<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302599</url>
  </required_header>
  <id_info>
    <org_study_id>CHIN-PLAGH-ST-003</org_study_id>
    <nct_id>NCT02302599</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells to Treat Type 2 Diabetes</brief_title>
  <acronym>UC-MSCs</acronym>
  <official_title>Efficacy and Safety of Umbilical-cord Mesenchymal Stem Cells in Chinese Adults With Type 2 Diabetes: a Single Center, Double-blind, Randomized, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Umbilical cord mesenchymal stem cells indicate the therapeutic effects and safety on type 2&#xD;
      diabetes by characteristics of secretion and immune Immunomodulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Umbilical cord mesenchymal stem cells can improve insulin resistance of the target tissues,&#xD;
      reduce the islet progressive damage, ease or regenerate of the islet beta cells and improve&#xD;
      hyperglycemic state of diabetes by secreting a variety of cytokines. It can induce damaged&#xD;
      alpha cells differentiate into beta cells in the islet transformation to realize the islet&#xD;
      beta cells in situ regeneration by improving microenvironment of islet beta cells. Umbilical&#xD;
      cord mesenchymal stem cells also have immunosuppressive effect, it can promote islet cell&#xD;
      repair and regeneration by the inhibition of T cell mediated immune response to beta cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>UC-MSCs (1.5×106/kg) or the same volume of placebo (suspension liquid without UC-MSCs)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All investigators and participants were masked to treatment allocation. The independent data monitoring committee and the statisticians supporting the committee's activities were the only people with access to unblinded data.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of umbilical cord mesenchymal stem cells in Chinese adults with T2D</measure>
    <time_frame>48 weeks from baseline</time_frame>
    <description>proportion of patients with HbA1c &lt;7.0% and daily insulin reduction ≥50% from baseline to 48 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other efficacy parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D</measure>
    <time_frame>48 weeks from baseline</time_frame>
    <description>Changes of insulin requirement, HbA1c and proportion of patients reaching the HbA1c target (&lt;7.0%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other efficacy parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D</measure>
    <time_frame>48 weeks from baseline</time_frame>
    <description>Change of islet β cell function and insulin resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D</measure>
    <time_frame>48 weeks from baseline</time_frame>
    <description>Fever, pruritus, nausea and vomiting, anaphylactic shock, phlebitis，tumor formation, infection, impaired liver and kidney function.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Mesenchymal Stem Cells</condition>
  <arm_group>
    <arm_group_label>Umbilical cord mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Umbilical cord mesenchymal stem cells intravenous infusion for three times with an interval of 4 weeks in the absence of disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controlled suspension liquid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Controlled suspension liquid</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical cord mesenchymal stem cells</intervention_name>
    <description>Infusion treatment</description>
    <arm_group_label>Umbilical cord mesenchymal stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Controlled suspension liquid</intervention_name>
    <description>Infusion treatment</description>
    <arm_group_label>Controlled suspension liquid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 20 ≤ age ≤ 65 years;&#xD;
&#xD;
          2. Duration of type 2 diabetes ≤20 years;&#xD;
&#xD;
          3. 24.0 kg/m2 ≤ BMI ≤40.0 kg/m2;&#xD;
&#xD;
          4. Stable exogenous insulin dose between 0.5-1.0 U/Kg/Day with or without oral&#xD;
             hypoglycemic agents (Dipeptidyl peptidase-4 (DPP-4) inhibitor, Glucagon like peptide 1&#xD;
             receptor (GLP-1R) agonist and Sodium-glucose co-transporter 2 (SGLT-2) inhibitor&#xD;
             excluded) for at least 3 months;&#xD;
&#xD;
          5. 7.0% ≤ HbA1c ≤ 12.0%;&#xD;
&#xD;
          6. Fasting C-peptide ≥ 1ng/ml;&#xD;
&#xD;
          7. Willingness to participate in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with ketonuria, tumor, serum creatinine level more than 175μmol/L, myocardial&#xD;
             infarction in the previous year, current angina or heart failure, more than one major&#xD;
             vascular event, retinopathy requiring laser treatment, malignant hypertension,&#xD;
             uncorrected endocrine disorder, occupations precluding insulin therapy;&#xD;
&#xD;
          2. Severe concurrent illness limiting life expectancy, inadequate understanding of the&#xD;
             study protocol, drug abuse, pregnant willing and allergic constitution.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>weidong HAN</last_name>
    <role>Study Director</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>yiming MU</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.301hospital.com.cn</url>
    <description>Chinese PLA General Hospital Endocrinology medical characteristics</description>
  </link>
  <reference>
    <citation>Hao H, Liu J, Shen J, Zhao Y, Liu H, Hou Q, Tong C, Ti D, Dong L, Cheng Y, Mu Y, Liu J, Fu X, Han W. Multiple intravenous infusions of bone marrow mesenchymal stem cells reverse hyperglycemia in experimental type 2 diabetes rats. Biochem Biophys Res Commun. 2013 Jul 5;436(3):418-23. doi: 10.1016/j.bbrc.2013.05.117. Epub 2013 Jun 11.</citation>
    <PMID>23770360</PMID>
  </reference>
  <reference>
    <citation>Wang XL, Lu JM, Pan CY, Mu YM, Dou JT, Ba JM. [Characteristics of the daily blood glucose profiles of impaired glucose tolerance and type 2 diabetes mellitus subjects by continuous glucose monitoring system]. Zhonghua Yi Xue Za Zhi. 2006 Mar 14;86(10):674-7. Chinese.</citation>
    <PMID>16681924</PMID>
  </reference>
  <reference>
    <citation>Si Y, Zhao Y, Hao H, Liu J, Guo Y, Mu Y, Shen J, Cheng Y, Fu X, Han W. Infusion of mesenchymal stem cells ameliorates hyperglycemia in type 2 diabetic rats: identification of a novel role in improving insulin sensitivity. Diabetes. 2012 Jun;61(6):1616-25. doi: 10.2337/db11-1141.</citation>
    <PMID>22618776</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 12, 2014</study_first_submitted>
  <study_first_submitted_qc>November 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Yiming Mu</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

